Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)

Recruiting

Phase 3

SolriamfetolStudying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)

Sponsor:

Axsome Therapeutics, Inc.

Code:

NCT06568367

Conditions

Excessive Sleepiness

Shift-work Disorder

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Not accepted

Interventions

Solriamfetol 150 mg

Solriamfetol 300 mg

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-12-16. This information was provided to ClinicalTrials.gov by Axsome Therapeutics, Inc. on 2025-11-25.